Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2015)
12 slides from Genetic Technologies's shareholder meeting presentation, Nov 27, 2015
Slide 1: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance
Slide 2: Major Achievements Since Last AGM
Major Achievements Since Last AGM Secured $24.0M Standby Equity Placement Facility Completed $18.6M capital raise Continued roll out of the 2nd generation BREVAGenplus test across the U.S. Revised sales and marketing strategy to target large comprehensive breast health centres and imaging centres Co
Slide 3: Operational Review
Operational Review Board and Management operational review, commenced at start of the fiscal year Strategic decision to shift the Company’s entire focus to the U.S. molecular diagnostics market Streamlined operations and focused on executing an ambitious commercial strategy for BREVAGenplus Decision
Slide 4: What is BREVAGenplus?
What is BREVAGenplus? Simple swab-based test that helps determine a woman’s risk of developing breast cancer Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation among people. The SNPs used in BREVAGenplus have been confirmed to be associated with Breast Cancer Molecu
Slide 5: What is BREVAGenplus? (swab-based test)
Simple swab-based test that helps determine a woman's risk of developing breast cancer Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation among people. The SNPs used in BREVAGenplus have been confirmed to be associated with Breast Cancer Molecular panel of 77 SNPs c
Slide 6: Market Opportunity
Market Opportunity Total number of women in target age range for BREVAGenplus: 54.3 million Potential market size reduced by: Ethnicities not covered by BREVAGenplus ~10% Women on Medicaid ~20% Of which ~33% are Women of intermediate risk, based on GAIL score Total target population ~12.9 million BU
Slide 7: Key Market Drivers
Key Market Drivers Scientific validation and clinical utility studies Further scientific validation results/publications expected by end Q2 FY16 Evidence from clinical utility studies will secure wider payer coverage, increase current reimbursement levels and speed product uptake – first of three tr
Slide 8: Market Progress
Market Progress BREVAGenplus now available in all 50 U.S. states Samples received from 18 high population density territories 8,558 Samples received since launch of BREVAGen, in June 2011, BREVAGenplus released in October 2014 Key Opinion Leaders (KOLs) act as BREVAGenplus Ambassadors to: Highlight
Slide 9: Geographical Cluster of Samples
Geographical Cluster of Samples Cumulative U.S. Samples cluster - July 2011 to June 2015 U.S. sales team focus on territories with high volume, demonstrating strong growth potential
Slide 10: Priorities for FY2016
Priorities for FY2016 SALES, SALES, SALES Complete scientific validation end Q2 FY16 and first of three clinical trials by end FY16, while commencing two other longer-term clinical trials in FY16 Strengthen the U.S. sales team, focus on improving scalability and creating market awareness of BREVAGen
Slide 11: Financial Snapshot
Financial Snapshot Shares outstanding 1,714 MM ADRs (@150:1 ratio) 8.9 MM Top 20 shareholders 86.4% Total shareholders 3,165 Unlisted Options outstanding 24.2MM As at 30 Jun 2015 - Market cap (@$0.028) AUD48.0 MM Fiscal Year Ended June 30 Financials Revenue (AUD millions) 2015 2014 2013 BREVAGen/ BR
Slide 12: Financial Snapshot
Financial Snapshot Fiscal Year Ended June 30 Financials Shares as at 30 June 2015 Revenue Shares outstanding 1,714 MM (AUD millions) ADRs (@150:1 ratio) 8.9 MM Top 20 shareholders 86.4% -2015 2014 2013. shareholders 3,165 BREVAGen/ Unlisted Options outstanding 24.2MM BREVAGenplus 1.3 1.7 0.3 As at 3
Genetic Technologies — Shareholder Meeting (November 2015) on 6ix